Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C and HIV infection; and the development of antibacterials for the treatment of resistant bacterial infections. Its products include ACH-1095, a NS4A antagonist that is in late-stage preclinical studies for the treatment of chronic hepatitis C infections; ACH-1625, a protease inhibitor, which is in the preparation for phase I initiation for the treatment of chronic hepatitis C infections; ACH-702, a preclinical candidate that is in preclinical stage with potency against a spectrum of bacterial pathogens, including methicillin-resistant staphylococcus aureus for drug resistant bacterial infections; and Elvucitabine, which completed phase II studies for the treatment of HIV infection. The company has a collaboration arrangement with Gilead Sciences, Inc. to develop and commercialize compounds for use in treating hepatitis C infection, which inhibit viral replication through a mechanism of action. The company was founded in 1998 and is based in New Haven, Connecticut.

Key Statistics

Closing Price	2.41
Volume	20800
Volume Avg	127241
52 Week High	3.89
52 Week Low	1.38
PE	N/A
PE (group average)	N/A
EPS Year	-0.86
EPS change Q/Q	-4.17%
EPS change Q/Q Yr ago	-24.24%
EPS change Q/Q next Q est	-56.25%
EPS change Y/Y	-49.48%
REV change Q/Q	-1000%
REV change Q/Q Yr ago	-1000%
EPS next Q est	-0.16
EPS next Y est	-0.47
Divident Annual	0.00
Dividend Yield	0%